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Introduction: Familial amyloid polyneuropathy is a rare autosomal dominant disorder caused by mutations in the
transthyretin gene, TTR. Diagnosis can be challenging, especially if other family members are not affected or an
obvious systemic involvement is lacking. The patients are often misdiagnosed, leading to a delay in the initiation
of therapy.
Case presentation: A 35-year-old woman of Turkish origin presented to our outpatient clinic with severe
polyneuropathy associated with distally pronounced tetraparesis and hypesthesia of 2 to 3 years’ duration. In
addition, small nerve fiber involvement with impaired detection of cold temperatures and tingling pain in the
lower legs was reported. She did not complain of autonomic dysfunction or visual disturbance. Her family history
was empty regarding neuromuscular disorders. The routine diagnostic work-up was unremarkable. A sural nerve biopsy
disclosed amyloid deposits, which led to the identification of a rare heterozygous transthyretin mutation (p.Glu74Gly;
old classification: p.Glu54Gly).
Conclusions: Few cases with this very heterozygous mutation can be found in the literature. In contrast to the case
of our patient, all of the previously described patients in the literature presented with additional severe autonomic
symptoms, involvement of the eyes and a positive family history. In this case report, we emphasize that, in patients
with progressive neuropathy with small fiber involvement, an amyloid neuropathy should be considered in the
differential diagnosis, even if the family history is empty and other organs are not affected.Introduction
Amyloid polyneuropathies are characterized by patho-
logical deposits of misfolded proteins and peptides in a
β-pleated sheet conformation, which induce damage and
a subsequent loss of large- as well as small-diameter nerve
fibers. Familial amyloidoses are rare diseases, especially in
nonendemic areas, and are divided into three subtypes
that present with different involvement of the peripheral
nervous system: transthyretin (TTR), apolipoprotein A-I
and gelsolin. TTR-associated familial amyloid polyneurop-
athy (TTR-FAP) is the most common type, in which amyl-
oid depositions in peripheral nerves lead to a progressive
sensorimotor and autonomic neuropathy. TTR-FAPs are* Correspondence: anne.schaenzer@patho.med.uni-giessen.de
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between 30 and 70 years, as well as an early (<50 years)
and late (>50 years) onset of presentation. A rapidly pro-
gressive polyneuropathy is described in most cases. More
than 100 mutations in the TTR gene are known, with
Val50Met (p.Val30Met) being the most common one. The
clinical manifestation can be very heterogeneous; thus, the
diagnosis is difficult and might be delayed, especially if
the patient is young and the family history negative [1-7].
Early diagnosis is important because treatment options
are available. In this report, we describe the clinical, elec-
trophysiological, histopathological and genetic findings in
a Turkish woman with a rapidly progressive type of TTR-
FAP. To the best of our knowledge, this report is the first
in the literature describing a patient who presented exclu-
sively with severe neuropathy as a symptom of the rare
p.Glu74Gly mutation.al Ltd. This is an Open Access article distributed under the terms of the Creative
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A 35-year-old woman of Turkish origin presented to our
outpatient clinic with increasing gait and stance distur-
bances of 2 or 3 years’ duration. She reported tingling pain
in the feet and lower legs as well as an impairment in de-
tecting cold temperatures as a sign of small fiber involve-
ment. In addition, the patient had recurrent shortness of
breath. She had previously been diagnosed with a severe
polyneuropathy of unknown origin. Besides the neur-
opathy, her medical history was empty. She denied gastro-
intestinal or visual disturbances.
She was a daughter of nonconsanguineous parents from
Turkey. Her family history was empty regarding neuro-
muscular disorders. She has four brothers and two sisters.
She is the mother of two healthy children (ages 5 and 7
years).
Her clinical examination revealed a distal as well as
left pronounced tetraparesis, hyporeflexia with absence
of Achilles tendon reflexes, hypesthesia of the lower legs
reaching the patellae and pallanesthesia at the medial
malleoli. No compound motor unit potential could be
measured on her lower extremities of the tibial or peroneal
nerves bilaterally. Motor conduction studies of her upper
extremities, including investigation of both the median
and ulnar nerves, were unremarkable. No sensory nerve
action potentials could be obtained on the upper or lower
extremities. Signs of denervation in the distal muscles of
the lower extremities, as well as signs of chronic neuro-
genic reorganization, were detected by electromyography.
The extensive polyneuropathy work-up and rheumatology
assessments did not produce any pathological results. No
indication for a paraneoplastic origin of the disease was
discovered. Standard screening methods did not reveal an
associated monoclonal gammopathy of undetermined sig-
nificance or diabetes. However, proteinuria was discovered
in the 24-hour urine collection, indicating renal involve-
ment. Because she had dyspnea, a cardiac work-up was
performed. In this clinical examination, minor signs of
chronic heart failure were found, and we classified her as
New York Heart Association functional class II. Magnetic
resonance imaging of her heart revealed early left ven-
tricular hypertrophy with a normal ejection fraction of
60%. Echocardiography showed an increased thickness of
the interventricular septum of 15mm and a slightly im-
paired longitudinal left ventricular function. The general
weakness might also have been associated with an involve-
ment of the autonomic nervous system with low systolic
blood pressure (generally 90mmHg or lower). The patient
did not complain about visual disturbances. However,
upon examination, opacity of the vitreous body with signs
of visual loss was detected in both eyes.
A sural nerve biopsy was performed and processed
using standard protocols [8]. Paraffin-embedded nerve
tissue was processed for Congo red staining. The staindepicted small but distinct endoneural deposits of amyl-
oid (Figure 1A) with a bright green birefringence under
polarizing filters (data not shown). These deposits
stained positive with antibodies against transthyretin
(TTR) (Figure 1B). Elastica van Gieson staining allowed
visualization of collagen fibers and showed a strong endo-
neural fibrosis (data not shown). Immunohistochemistry
against neurofilament and p-phenylenediamine-stained
semithin sections revealed peripheral nerve fascicles with
severe loss of myelinated fibers (about 95% compared to
healthy controls) and only few remaining myelinated fi-
bers (Figures 1C and 1D). Single fibers with acute myelin
degradation could be observed. Electron microscopy con-
firmed the severe axonal neuropathy with few remaining
myelinated fibers with signs of axonal atrophy, few myelin
debris and denervated Schwann cell bands (Figures 1E
and 1F). Additionally, a severe loss of unmyelinated fibers
could be detected. Single amyloid deposits were demon-
strated by ultrastructural analysis. There were no signs of
axonal regeneration.
In the genetic analyses of the TTR gene, we found a het-
erozygous missense mutation: c.221A>G (GAG>GGG;
p.Glu74Gly). The four coding exons of TTR, correspond-
ing to coding cDNA nucleotides c.1 to c.444, including
flanking sequences, were amplified by PCR and screened for
mutations by direct sequencing (reference sequence: TTR
ENSG00000118271 with transcript ENST00000237014).
Mutation designation according to standard naming con-
ventions of the Human Genome Variation Society [9],
which uses numbering beginning at the Met initiation
codon, includes a 20–amino acid signal sequence and may
be different from that reported in the literature. The alter-
native mutation designation for the mutation detected in
our patient is p.Glu54Gly.
Treatment with tafamidis was initiated after TTR-FAP
was diagnosed [10], but our patient’s neuropathy was ag-
gravated nonetheless. An orthotopic liver transplant was
performed 10 months later, but the patient died as a re-
sult of intra-operative complications. Three of her four
brothers and three sisters have since presented to our out-
patient clinic. A 36-year-old brother tested positive for
amyloid in a subcutaneous fat aspiration test. Further
family members in Turkey have been evaluated for the
mutation. One cousin was found to be a mutation carrier;
unfortunately, we have no further information on his
health condition.
Discussion
Hereditary amyloidoses with a predominant involvement
of the peripheral nervous system are rare and often diffi-
cult to diagnose, especially when other family members are
not affected. The patients are often misdiagnosed, leading
to a delay in the initiation of therapy. In our patient, a rap-
idly progressive neuropathy with initial symptoms of small
Figure 1 Sural nerve biopsy sections. Small endoneural amyloid deposits are shown in the Congo red staining (A) with a positive transthyretin
antibody reaction (B). There is a severe axonal loss with antibodies against neurofilament (C). In the p-phenylenediamine-stained semithin sections,
only a few remaining myelinated axons (arrow) can be seen, and acute myelin degeneration (arrowhead) is present (D). Electron microscopic images
show denervated Schwann cell bands (arrows) (E) and axonal degeneration with myelin debris (arrow) (F).
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findings were the nerve biopsy with endoneural amyloid
deposits and a severe loss of myelinated and unmyelinated
fibers in the absence of signs of regeneration.
Some rare mutations of familial amyloid neuropathies
are associated with an early onset and a rapid disease pro-
gression. Patients with the rare mutation in p.Glu74Gly
(pGlu54Gly) usually present with a positive family history
and have severe autonomic disturbance causing gastro-
intestinal symptoms, such as vomiting, constipation and
diarrhea, of many years’ duration [6,11,12]. Moreover,
blindness is an early phenomenon in patients with a muta-
tion in Glu54Gly [11,12]. Our patient did not have any of
these symptoms. Although she did not complain about
visual disturbances, opacity of the vitreous body with signs
of visual loss could be detected.In this report, we present the case of a 35-year-old
woman of Turkish origin who had TTR-FAP with a rare
mutation with a phenotype different from those in other
cases reported in the literature so far. First, our patient’s
family history was unremarkable. Second, she reported
small fiber involvement in the sense of a small fiber neur-
opathy without typical autonomic signs. Early involvement
of small nerve fibers (Aδ and C fibers) in TTR-FAP pa-
tients is well described in the literature [3,7,13-15]. How-
ever, the typical autonomic disturbances described in
patients with a mutation in Glu54Gly, such as gastrointes-
tinal symptoms, were completely absent in our patient.
Third, no visual disturbances were present; however, upon
examination, opacity of the vitreous body could be de-
tected. Therefore, the severe polyneuropathy was the only
symptom of this very rare mutation in our patient.
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An amyloid neuropathy should be considered in patients
with progressive neuropathies, even if the neuropathy
is the only complaint and the patient’s family history
is negative.
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